海爾生物(688139.SH):目前在歐盟不存在單個招標採購合同金額超過500萬歐元的項目
格隆匯6月27日丨海爾生物(688139.SH)在互動平台表示,依據《國際採購工具》(IPI)規定,歐盟委員會決定限制中國企業參與價值超500萬歐元的醫療器械招標。公司目前在歐盟不存在單個招標採購合同金額超過500萬歐元的項目,該項政策對公司業務基本沒有直接影響。公司海外業務廣泛佈局於非洲、歐洲、亞太、美洲等區域,並不斷推進跨區域、跨渠道、跨品類的全球化佈局,已經形成以英國、荷蘭、美國、新加坡、印度等國家為核心輻射周邊的當地化團隊,累計擁有海外產品認證400餘個。後續公司將密切關注政策變化,從生產、研發、市場等多方面,持續提升公司抗風險能力和全球市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.